Related Experiment Video

Updated: Aug 10, 2026

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

[Changes in blood hormone levels in gout and methods of their correction (an experimental and clinical study)]

I V Mukhin, G A Ignatenko

    Klinicheskaia Laboratornaia Diagnostika
    |March 7, 2003
    PubMed

    Insights

    Gout is linked to hormonal imbalances, specifically in the hypophysis-gonad system. Testosterone therapy shows promise in normalizing purine metabolism and improving gout symptoms.

    Area of Science:

    • Rheumatology
    • Endocrinology
    • Pathophysiology

    Context:

    • Gout incidence is rising in European men.
    • Current gout therapies have limited effectiveness.
    • Dishormonal disorders are increasingly discussed in gout pathogenesis.

    Purpose:

    • To investigate the role of hypophysis-gonad system disorders in gout pathogenesis.
    • To explore the therapeutic potential of androgens in gout.

    Summary:

    • Gout patients exhibit hypophysis-gonad system disorders, including progesterone overproduction and suppressed testosterone/estradiol.
    • Experimental purine metabolism disruption induced similar hormonal changes, suggesting secondary hormonal dysfunction.
    • Androgen administration in experimental hyperuricemia normalized purine metabolism and hormone levels, reducing arthritis signs.

    Impact:

    • Findings suggest a link between hormonal imbalances and gout development.
    • Androgen therapy, including testosterone and analogues, demonstrates superior effectiveness compared to existing gout treatments.
    • This research opens new avenues for pathogenetic gout therapy.

    Related Concept Videos

    Hypertension and Regulation of Blood Pressure01:18

    Hypertension and Regulation of Blood Pressure

    Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...